DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tazemetostat
Tazemetostat
Malignant Pleural Mesothelioma: State- Of-The-Art on Current Therapies and Promises for the Future
Targeting EZH2 for the Treatment of Soft Tissue Sarcomas
Epithelioid Sarcoma—From Genetics to Clinical Practice
Use of the Tree-Based Scan Statistic for Surveillance of Infant Outcomes Following Maternal Perinatal Medication Use Appendices: Code Lists
Tazemetostat (Tazverik™) EOCCO POLICY
Soft Tissue Sarcoma: an Insight on Biomarkers at Molecular, Metabolic and Cellular Level
Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: a View on Paradoxical Roles of KDM6B and EZH2
Targeting Epigenetics in Sarcomas Through EZH2 Inhibition Antoine Italiano1,2,3
TAZVERIK (Tazemetostat) Tablets, for Oral Use Patients Long-Term for the Development of Secondary Malignancies
Tazemetostat in Treating Patients with Relapsed Or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, Or Histiocytic Disord
United States Securities and Exchange Commission Washington, D.C
View Presentation
Dosimétrie Basée Sur L'imagerie Pour L'optimisation De La Thérapie Photodynamique Pour Le Mésothéliome Pleural Malin
H3k27me3 and EZH2 Expression in Melanoma
Epizyme Announces Updated Tazemetostat Phase 1 Data Showing Clinical Activity in a Broader Range of Adults with INI1-Negative and SMARCA4-Negative Solid Tumors
Oral Presentations
Epizyme Presents Data from a Phase 1 Trial of Tazemetostat in Children
Emtree Terms Changed in September 2013
Top View
Approved in Japan for Ezh2 Gene Mutation-Positive Follicular Lymphoma
Multi-Discipline Review
Tazemetostat (Tazverik) Reference Number: CP.PHAR.452 Effective Date: 03.01.20 Last Review Date: 02.21 Line of Business: Commercial, HIM, Medicaid Revision Log
Therapeutic Advances in Oncology
Multi-Discipline Review
(EPZ-6438) Plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
NCTN Trial Portfolios
FDA Briefing Document Oncologic Drugs Advisory Committee Meeting
PRESCRIBING INFORMATION • Embryo-Fetal Toxicity: Can Cause Fetal Harm
BC Cancer Agency 2015 Research Report
Immunotherapy for Chordoma and Chondrosarcoma: Current Evidence
Overview of Malignant Solid Tumors in Neonates International Journal of Pediatrics & Neonatal Care
Molecular Targets and Novel Therapeutic Avenues in Soft-Tissue Sarcoma
A Closer Look at Tazemetostat
Fact Sheet on Epithelioid Sarcoma
NDA 211723: Tazemetostat FDA Opening Remarks
View Annual Report
Tazemetostat for the Treatment of Pediatric Patients with Malignant Rhabdoid Tumors and Other INI1-Negative Tumors